Supernus Pharmaceuticals Inc (SUPN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Supernus Pharmaceuticals Inc (SUPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012206
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Supernus Pharmaceuticals Inc (Supernus) is a specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; and Trokendi XR (topiramate), an initial monotherapy against partial onset or primary generalized tonic-clonic seizures and an adjunct therapy for the treatment of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome. Its technology platforms include Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The company operates through its subsidiary Supernus Europe Ltd. Supernus is headquartered in Rockville, Maryland, the US.

Supernus Pharmaceuticals Inc (SUPN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Supernus Pharma Secures US$15 Million In Venture Financing 10
Supernus Pharma Raises US$15 Million In Venture Financing 11
Private Equity 12
HealthCare Royalty Acquires Orenitram from Supernus Pharma for USD30 Million 12
Licensing Agreements 13
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 13
Aequus Pharma Enters into Licensing Agreement with Supernus Pharma 14
Equity Offering 15
Supernus Pharma Completes Public Offering Of Common Stock For US$48 Million 15
Supernus Pharma Completes IPO For USD52.3 Million 17
Debt Offering 19
Supernus Pharma Completes Private Placement Of Notes Due 2019 For US$90 Million 19
Acquisition 21
Supernus Pharma Sells TCD Royalty Sub For US$27 Million 21
Supernus Pharmaceuticals Inc – Key Competitors 22
Supernus Pharmaceuticals Inc – Key Employees 23
Supernus Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 06, 2017: Supernus Announces Third Quarter 2017 Financial Results 25
Aug 02, 2017: Supernus Announces Record Second Quarter 2017 Financial Results 27
May 09, 2017: Supernus Announces First Quarter 2017 Financial Results 29
Feb 28, 2017: Supernus Announces Record Fourth Quarter and Full Year 2016 Financial Results 31
Aug 02, 2016: Supernus Announced Second Quarter 2016 Financial Results 33
Aug 02, 2016: Supernus Announces Second Quarter 2016 Financial Results 35
May 03, 2016: Supernus Announces First Quarter 2016 Financial Results 37
Mar 02, 2016: Supernus Announces Record Fourth Quarter and Full Year 2015 Financial Results 39
Corporate Communications 41
Aug 12, 2016: Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman 41
Other Significant Developments 42
Nov 14, 2016: Supernus Provides Business Update 42
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Supernus Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Supernus Pharma Secures US$15 Million In Venture Financing 10
Supernus Pharma Raises US$15 Million In Venture Financing 11
HealthCare Royalty Acquires Orenitram from Supernus Pharma for USD30 Million 12
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 13
Aequus Pharma Enters into Licensing Agreement with Supernus Pharma 14
Supernus Pharma Completes Public Offering Of Common Stock For US$48 Million 15
Supernus Pharma Completes IPO For USD52.3 Million 17
Supernus Pharma Completes Private Placement Of Notes Due 2019 For US$90 Million 19
Supernus Pharma Sells TCD Royalty Sub For US$27 Million 21
Supernus Pharmaceuticals Inc, Key Competitors 22
Supernus Pharmaceuticals Inc, Key Employees 23
Supernus Pharmaceuticals Inc, Subsidiaries 24

★海外企業調査レポート[Supernus Pharmaceuticals Inc (SUPN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bank of Baroda:企業のM&A・事業提携・投資動向
    Bank of Baroda - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of Baroda Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • United Therapeutics Corp (UTHR):企業の製品パイプライン分析
    Summary United Therapeutics Corp (United Therapeutics) develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension and infectious diseases. The company's products consist of prostacyclin analogues includin …
  • Canada Energy Partners Inc (CE):企業の財務・戦略的SWOT分析
    Summary Canada Energy Partners Inc (Canada Energy) is a natural gas exploration and development company. The company concentrates on mid-stream supplying of water disposal services, development of a wellbore mining technology and energy or mineral exploring. Canada Energy develops a wellbore mining …
  • Minnesota Municipal Power Agency:企業の戦略的SWOT分析
    Minnesota Municipal Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Spire Inc (SR):石油・ガス:M&Aディール及び事業提携情報
    Summary Spire Inc (Spire), formerly Laclede Group, Inc., is a public utility, which carries out the sale, marketing and retail distribution of natural gas. It also markets natural gas and related activities on a non-regulated basis. The company also conducts transportation of liquid propane; real es …
  • Emerson Radio Corporation (MSN):企業の財務・戦略的SWOT分析
    Emerson Radio Corporation (MSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Aslan Pharmaceuticals Pte Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd is a biotechnology company that offers immuno-oncology agents and targeted therapies. The company’s pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhibi …
  • Ultra Petroleum Corp (UPL):石油・ガス:M&Aディール及び事業提携情報
    Summary Ultra Petroleum Corp (Ultra) is an independent upstream company, which develops, produces, operates, explores, and acquires oil and natural gas properties. It develops long-life natural gas reserves in the Green River Basin of Wyoming, the Pinedale and Jonah fields, and oil reserves in the U …
  • Hualan Biological Engineering Inc (002007):企業の財務・戦略的SWOT分析
    Summary Hualan Biological Engineering Inc (Hualan Biological) is a biopharmaceutical company that develops vaccines. The company conducts research, develops and produces plasma, vaccines and gene products. Its plasma products include surgical lyophilized fibrin sealant, human coagulation factor VIII …
  • Standard Alliance Insurance Plc:企業の戦略・SWOT・財務情報
    Standard Alliance Insurance Plc - Strategy, SWOT and Corporate Finance Report Summary Standard Alliance Insurance Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Power Finance Corporation Ltd.:企業の戦略・SWOT・財務情報
    Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • BNC Bancorp:企業のM&A・事業提携・投資動向
    BNC Bancorp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BNC Bancorp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Tien Phong Commercial Joint Stock Bank (TPB):企業の財務・戦略的SWOT分析
    Tien Phong Commercial Joint Stock Bank (TPB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Selective Insurance Group, Inc. (SIGI):企業の財務・戦略的SWOT分析
    Selective Insurance Group, Inc. (SIGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Autotelic Inc-製薬・医療分野:企業M&A・提携分析
    Summary Autotelic Inc (Autotelic) is a therapeutic drug monitoring company that develops novel treatments using its therapeutic drug monitoring (TDM) services. The company's pipeline products includes devices to improve safety and efficacy of COX-2 inhibitors, paclitaxel nanomedicine and TGF-beta in …
  • ESSA Pharma Inc (EPI):企業の財務・戦略的SWOT分析
    Summary Essa Pharma Inc (Essa Pharma) is a drug developer that offers oncology therapeutics. The company develops EPI-506, disrupts androgen receptor transcriptional activity through selectively blocking the N-terminal domain of the AR. It also conducts research on prostate cancer and the androgen r …
  • KS Energy Ltd (578):企業の財務・戦略的SWOT分析
    KS Energy Ltd (578) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Bouygues SA (EN):電力:M&Aディール及び事業提携情報
    Summary Bouygues SA (Bouygues) is an industrial group which operates in construction, real estate development, media and telecommunication markets. It undertakes construction contracts for roads, airport runways, seaport, industrial infrastructure, parking areas, recreational facilities, electrical …
  • Falck Renewables SpA (FKR)
    Falck Renewables SpA (FKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Ten Network Holdings Ltd:企業の戦略的SWOT分析
    Ten Network Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆